Reference - Detail
|Author||Sakuma M, Akahira J, Ito K, Niikura H, Moriya T, Okamura K, Sasano H, Yaegashi N.|
|Title||Promoter methylation status of the Cyclin D2 gene is associated with poor prognosis in human epithelial ovarian cancer.|
2 cm) (P = 0.027 and P = 0.031, respectively). Based on univariate analysis, patients with aberrant methylation of the Cyclin D2 promoter had a significantly worse chance of disease-free survival than those without methylation (P = 0.021). Our results suggest that aberrant promoter methylation of the Cyclin D2 gene is significantly associated with patient prognosis in epithelial ovarian cancer.
|MeSH||Antimetabolites, Antineoplastic / pharmacology Azacitidine / analogs & derivatives Azacitidine / pharmacology Cell Line, Tumor Cyclin D2 Cyclins / genetics* Cyclins / metabolism DNA Methylation* Decitabine Enzyme Inhibitors / pharmacology Female Humans Hydroxamic Acids / pharmacology Immunohistochemistry Ovarian Neoplasms / diagnosis* Ovarian Neoplasms / genetics Ovarian Neoplasms / metabolism* Ovarian Neoplasms / pathology Prognosis Promoter Regions, Genetic* RNA, Messenger / analysis Retrospective Studies Reverse Transcriptase Polymerase Chain Reaction|
|Human and Animal Cells|